Atlas Trials

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

Clinical trial NCT02638038 · COMPLETED

Trial details

NCT number
NCT02638038
Sponsor
InteKrin Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing Remitting
Start date
2015-02-01
Primary completion
2016-12-12
Enrollment
228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.